Objective: Disease-modifying osteoarthritis drugs (DMOADs) are under development. Our goal was to 3 determine efficacy, toxicity, and cost thresholds under which DMOADs would be a cost-effective knee 4 OA treatment. 5 6 Design: We used the Osteoarthritis Policy Model, a validated computer simulation of knee OA, to 7 compare guideline-concordant care to strategies that insert DMOADs into the care sequence. The 8 guideline-concordant care sequence included conservative pain management, corticosteroid injections, 9 total knee replacement (TKR), and revision TKR. Base case DMOAD characteristics included: 50% 10 chance of suspending progression in the first year with a resumption rate of 10% in every subsequent 11 year with 30% pain relief among those whose progression was suspended; 0.5%/year risk of major 12 toxicity; and costs of $1,000/year. In sensitivity analyses, we varied the suspension of OA progression 13 (20-100%), pain relief (10-100%), major toxicity (0.1-2%), and cost ($1,000-$7,000). Outcomes 14 included costs, quality-adjusted life expectancy, incremental cost-effectiveness ratios (ICERs), and 15
INTRODUCTION 1 2
Knee osteoarthritis (OA) is a prevalent and costly disease characterized by structural changes in 3 cartilage, bone, synovium, and other joint structures 1 . Symptomatic knee OA is a leading cause of 4 disability, afflicting more than 9.3 million US adults aged 26 years and older 2 . The population at risk for 5 knee OA is growing substantially due to the aging population, obesity epidemic, and an increasing rate 6 of knee injuries in young, active individuals 1, [3] [4] [5] [6] [7] . 7 8 Current guidelines for knee OA care focus on pain relief and functional improvement and include the 9 use of non-pharmacologic and pharmacologic therapies early in the course of the disease
8-10
. 10
Pharmacologic therapies are only modestly efficacious and have significant associated toxicities. For 11 example, non-steroidal anti-inflammatory drugs (NSAIDs) pose gastrointestinal and cardiovascular 12 risks [11] [12] [13] . There are no currently approved OA treatments capable of slowing OA-related structural 13 progression or delaying the need for total knee replacement (TKR). Several large pharmaceutical 14 companies are in the late stages of developing and testing such disease-modifying OA drugs 15 (DMOADs), and promising agents that may both halt progression and provide symptom relief 16 are currently being studied [14] [15] [16] [17] . 17
18
In light of ongoing efforts to develop DMOADs, we sought to address several key questions: Can 19
DMOADs be cost-effective, and if so, at what levels of efficacy, toxicity, and cost? How early in the 20 course of treatment should DMOADs be initiated? Do DMOADs have the potential to reduce TKR 21 utilization? To address these key issues, we propose a novel framework in which model-based 22 evaluations of cost-effectiveness can be used to pre-evaluate new treatment strategies before the 23 treatments are actually in widespread use. Estimating the effects of particular features of a medication 1 on that medication's cost-effectiveness can inform the design of trials and provide performance targets. 2 3 METHODS 1 2
Analytic Overview 3 4
We used the Osteoarthritis Policy (OAPol) Model, a validated state-transition computer simulation 5 model, to compare clinical outcomes and costs for subjects receiving guideline-concordant treatments 6 (the standard of care), to subjects receiving standard of care and DMOADs 18, 19 . Outcomes included 7 costs, quality-adjusted life expectancy (QALE), incremental cost-effectiveness ratios (ICERs, the ratio 8 of change in costs to change in QALE), and TKR utilization. In conformity with accepted practice, 9 strategies that increased cost while decreasing QALE relative to an alternative treatment strategy were 10 referred to as "Dominated." We performed the analysis from the health systems perspective (indirect 11 costs were not included in the main analysis), with costs and QALE discounted at a rate of 3%/year ). Each year, 20 subjects may develop a comorbid condition, increase in BMI, progress in OA severity, and/or die. 21
Progression of OA is defined as an increase by one Kellgren-Lawrence (K-L) radiographic grade and is 22 dependent on obesity status and sex 21 . The model considers five comorbid conditions: coronary heart 23 disease, diabetes mellitus, chronic obstructive pulmonary disease, cancer, and musculoskeletal 24 disorders other than OA. The prevalences of these comorbid conditions depend on age, sex, 1 race/ethnicity, and obesity [22] [23] [24] . Each subject is followed until death, which may occur in any health 2 state. The OAPol Model uses underlying mortality rates from US life tables with excess mortality due to 3 specific comorbid conditions removed. The life tables are stratified by sex and race/ethnicity 25 . 4
Individuals with comorbid conditions, or who are underweight, obese, or morbidly obese have greater 5 risk of death 26, 27 . Subjects with knee OA may receive OA treatments, which are characterized by the 6 ability to relieve pain and suspend the progression of OA, toxicity, and cost. OA treatments may carry 7 major (e.g. gastrointestinal bleeding) and minor (e.g. dyspepsia, rash) toxicities, both of which decrease 8 quality of life and increase costs. Major toxicities lead to regimen discontinuation and may also cause 9 death. 10 11 Each year, subjects accrue costs and changes in quality of life due to OA or OA-related treatments, 12 other underlying medical conditions, or toxicity from treatment. Quality of life weights are assigned to 13 capture preferences for health states; a value of 1.0 denotes a state of perfect health while a value of 14 zero denotes health states that are preferentially equivalent to death 28 . Annual medical costs not 15 directly attributable to knee OA treatment are based on number of comorbidities, obesity, and 16 age 22, 23, 29, 30 . These data are presented in Table 1 . Subjects progress to the next regimen in the 25 sequence only when the current treatment fails or if a major toxicity occurs. Failure of each regimen is 1 assumed to be detected in the year it occurs. Fundamental treatment characteristics for the standard of 2 care are presented in Table 1 . DMOADs: We evaluated treatment strategies where DMOADs were used after the first standard of care 7 regimen and before the second standard of care regimen. Figure 1 illustrates the treatment 8 sequence for individuals receiving DMOADs. There are two measures of DMOAD treatment 9 efficacy: structural efficacy and pain relief. Structural efficacy is defined by a relative reduction in the 10 probability of progressing from one K-L grade to the next. Subjects for whom DMOADs suspend OA 11 progression (i.e. DMOADs exhibit structural efficacy) remain at their current K-L grade. Subjects in 12 whom structural progression is suspended may also experience pain relief and a consequent reduction 13 in costs and improvement in quality of life. To ensure a conservative approach with respect to the 14 clinical value of DMOADs, we assume that DMOAD-related pain relief is restricted to subjects in whom 15 knee OA progression is suspended. Delaying progression at earlier stages of the disease prevents 16 decrements in quality of life associated with advanced OA (K-L grade 3 or 4). While on DMOADs, 17 individuals accumulate annual treatment costs. Subjects experiencing toxicity (major or minor) have a 18 decrement in quality of life for that year and incur costs to treat the toxicity. Major toxicity carries a small 19 risk of death. Subjects are removed from DMOADs and move on to the next treatment in the sequence 20 if DMOADs fail to suspend progression and that failure is detected or if a major toxicity occurs. with clinicians and review of available literature. In the base case, we assumed that DMOADs 6 suspended OA progression in 50% of subjects. Among those in whom DMOADs succeeded in 7 suspending progression in the first year, there was a 10% failure rate of maintaining the suspension of 8 progression in every subsequent year. We further assumed that once disease progression resumed, it 9 could no longer be suspended via DMOADs. For the base case analysis we chose to anchor pricing for 10 DMOADs at $1,000/year, similar to the cost of prescription NSAIDs
30
. In addition to the baseline cost of 11 DMOADs, we also considered the cost of one office visit per year: $132 in the first year and $93 in 12 subsequent years (reflecting higher costs for new patient visits) 32 . 13
14
In practice, monitoring for drug failure is typically triggered when patients report the persistence or 15 recurrence of pain. Since drug failures to suspend disease progression would be accompanied by pain, 16
we therefore assumed that all DMOAD failures would be detected in the year they occurred, resulting in 17 discontinuation of DMOADs and allowing subjects to advance to the next treatment regimen in the 18 following cycle. We assumed the base case likelihood of pain relief was 30% given that progression 19 was suspended (that is, 15% overall likelihood of pain relief). Among patients whose structural 20 progression had been suspended due to DMOADs and who experienced initial pain relief, there was a 21 1%/year chance of losing pain relief. The failure to sustain pain relief reflects a multitude of factors 22 including suboptimal adherence and accumulation of additional risk factors such as injury. 23
24
We anchored values for both major and minor toxicities of DMOADs to NSAID toxicity characteristics. 1
The cohort of individuals eligible to receive DMOADs will be similar to the population currently utilizing 2 NSAIDs for OA pain; thus, acceptable DMOAD adverse event rates are likely to be comparable to 3 those of NSAIDs. The likelihood of major toxicity was assumed to be 0.5% per year, based on the 4 major toxicity risks of Cox-2 selective NSAIDs 11, 33 . DMOAD minor toxicity was modeled after the toxicity 5 of non-selective NSAIDs, with 9.50% risk in the first year, and 7.27% risk in all subsequent years 34, 35 . In 6 the base case analysis, we assumed that annual imaging studies to detect failure were included in the 7 cost of the DMOAD regimen. We varied each of DMOAD parameters listed in Table 1 24 . In the absence of efficacious DMOADs, annual OA progression rates (percentage of subjects 18 who worsened in K-L grade in a year) ranged from 1.29% for non-obese K-L grade 3 males to 12.26% 19 for obese K-L grade 2 males 19 . Annual underlying (not related to OA management) medical costs (USD 20 2010) ranged from $1,302 for young subjects with at most one comorbid condition and no OA pain to 21 $18,877 for older subjects with symptomatic OA and greater than three comorbid conditions 22, 23, 30, [37] [38] [39] . 22
Quality of life weights were derived by converting responses to general health status questions in the 23 National Health and Nutrition Examination Survey (NHANES) [2005] [2006] [2007] [2008] to health status ratings on a 24 scale of zero to 1.0 22, 23, 40, 41 . These ratings were then transformed to preference-based utilities 42 . 18, 19 . Please refer to the supplementary technical appendix for 6 more information. 7 8
Sensitivity Analyses 9 10

Two-way Sensitivity Analyses of DMOAD Characteristics 11
We conducted 21 sets of two-way sensitivity analyses, varying likelihood of suspending OA 12 progression, pain relief, major toxicity, loss of pain relief and/or resumption of OA progression, and 13 costs. We tested the sensitivity of DMOAD cost-effectiveness to variations in the initial likelihood of 14 suspended progression (20% -100%), failure to suspend progression in subsequent years (1% -10%), 15 initial pain relief (10% -100%), failure to relieve pain in subsequent years (1% -10%), cost ($1,000 -16 $7,000), and major toxicity (0.1% -2%) in a series of two-way sensitivity analyses.
By modeling 17
DMOADs with low levels of pain relief (10%), we incorporated the possibility that DMOADs may 18 not necessarily provide pain relief, even if they suspend progression. These ranges were 19 chosen to cover the spectrum of possible DMOAD characteristics. Costs and toxicity were 20 specifically anchored to known values for NSAIDs. 21
22
Additional Sensitivity Analyses 23
In addition to varying levels of DMOAD efficacy, toxicity, and cost, we varied the timing of DMOAD 1 administration, defined by where in the sequence of current standard of care DMOADs are inserted. 2
We also varied the placement of the regimens by switching the order of Regimen 1 (NSAIDs, 3 physical therapy, acetaminophen) and Regimen 2 (cortico-steroid injections). We also tested 4 the effect of removing Regimen 2 (cortico-steroid injections) from the treatment sequence. Figure 3 shows the minimal degree of structural OA progression suspension and pain relief at which 3 DMOADs might be considered cost-effective using three different cost-effectiveness thresholds: 4 $50,000/QALY, $100,000/QALY, and $150,000/QALY. Assuming DMOADs are associated with 0.5% 5 risk of major toxicity and failure of DMOADS is diagnosed in the year it occurs, DMOADS costing 6 $1,000/person/year would achieve ICERs below $50,000/QALY if they could suspend OA progression 7 by at least 60% and provide concurrent pain relief in at least 30% of those with suspended OA 8 progression. DMOADs that cost $3,000 or $5,000 would attain ICERs below $100,000/QALY if they 9 could suspend OA progression/lead to pain relief by at least 20%/70% or 60%/60%. ICERs below 10 $150,000/QALY could be achieved by DMOADs costing $7,000/person/year if they could suspend 11 structural progression by at least 20% and lead to concomitant pain relief in at least 90% of those with 12 suspended OA progression. Figure 3 shows that DMOADs costing $1,000, suspending progression in 13 100% of cases, and leading to 20% pain relief would provide similar value as more expensive DMOADs 14 ($3,000/person/year) that suspend progression in 20% of cases, and relieve pain in 70% of cases. The 15 same value would also be achieved by a more expensive DMOAD ($5,000) with pain relief and 16 suspended progression at 60%. DMOADs costing $7,000 were unlikely to attain ICERs of 17 $50,000/QALY, even if they were 100% effective in both suspending structural progression and 18 relieving pain. 19 20
Sensitivity Analyses 21 22
Select, 2-way sensitivity analyses are presented in Figure 4 and Tables 2 and 3. Additional 2-way 23 sensitivity analyses are presented in the Technical Appendix. The timing of DMOAD administration 24 (anywhere in the sequence prior to TKR) did not have a meaningful impact on the cost-effectiveness of 1 DMOAD therapy (results not shown). 2 3 Table 2 presents results of two-way sensitivity analyses that varied the degree of suspended 4 progression and pain relief within clinically plausible ranges (50-70% for suspended progression and 5 30-50% for pain relief). When DMOADs were priced at $1,000/year with major toxicity risks at 6 0.5%/year, DMOADs were likely to have cost-effectiveness ratios below $100,000 compared to the 7 standard of care (no DMOADs). The proportion of the cohort receiving TKR depended on the likelihood 8 that DMOADs suspended progression; base case DMOADs as the second-line regimen (50% 9 suspended progression, 30% concomitant pain relief) resulted in 40.72% lifetime risk for TKR. 10
Increasing suspended progression to 70% decreased lifetime risk of TKR to 37.82%. Table 3 Position]  2   3   Table 3 presents results of two-way sensitivity analyses examining the impact of DMOAD cost, efficacy, 4 and toxicity. Improved pain relief (50%) achieved concurrently with suspended progression of 50% led 5 to very favorable cost-effectiveness ratios (<$50,000/QALY); however, ICERs increased over 6 $50,000/QALY when DMOADs were priced at $2,000 or $3,000 annually. Priced at $1,000/year, 7
DMOADs had favorable ICERs across a wide range of plausible values for pain relief, toxicity, and 8 likelihood of suspended progression. OA, we have demonstrated that cost, efficacy, and pain relief are the key drivers of value in DMOADs. 5
We also have shown how these drivers trade off with one another. In addition, we have described the 6 many plausible combinations of these drivers which could reduce the need for TKR and satisfy 7 commonly cited cost-effectiveness criteria. There is no general agreement about what defines "cost-8
effective." In the United States, maximum willingness-to-pay thresholds ranging from $50,000/QALY to 9 $150,000/QALY and beyond are widely cited [45] [46] [47] . 10
11
The cost-effectiveness of DMOADs was highly sensitive to variations in those parameters with direct 12 effects on quality of life, particularly pain relief. Variations in the level of pain relief revealed a distinct 13 threshold of 20%, below which DMOADs would not offer clinical benefits relative to standard care. 14 DMOADs with no intrinsic pain-relieving capacity could only improve quality of life if slowing down 15 progression ultimately reduced painful OA. Our results validate the importance of targeting pathways 16 which will both reduce progression and offer pain relief. 17
18
Since improvements in quality of life are anchored in pain relief, the cost-effectiveness of DMOADs 19 ultimately depends on the level of overall symptom relief achieved by suspended structural progression. 20
Greater rates of suspended OA progression were associated with a lower proportion of the cohort 21 receiving TKR; however, the reduced TKR rates did not translate to greater cost-effectiveness unless 22
DMOADs also offered pain relief because, while TKR is costly, it consistently provides pain relief. Thus, 23 in order to justify prolonged DMOAD use before TKR, even in cases of suspended progression, 1 DMOADs must offer pain relief. 2 3 Several important limitations of our analyses should be considered when interpreting our results. Our 4 measure for progression of OA was the K-L grade, which does not detect bone marrow lesions, 5 significant contributors to OA pain 48, 49 . While an MRI-based definition of OA and its progression is 6 receiving growing attention, the validation of MRI-based markers is ongoing 50 . In order to address this 7 limitation and maintain conservative estimates of pain relief, we did not model pain relief as 8 automatically occurring in cases of suspended progression; rather, in the base case only 30% of 9 subjects experiencing suspended progression also experienced pain relief. Moreover, in the model, the 10 efficacy of DMOADs was expressed in terms of slowing or 'suspending' progression based on K-L 11 grade. However, K-L grade is a relatively unresponsive marker of radiographic change and its use may 12 lead to increased time until DMOAD failure detection We did not consider high-tibial osteotomy (a treatment option for subjects with uni-6 compartmental disease) as part of the standard treatment sequence. In order to make results 7 generalizable to the overall population with knee OA, we chose to simulate the most common 8
OA treatments. 9 10
The cost-effectiveness thresholds may vary from country to country. The results presented in 11 this paper are based on cost and quality of life data measured in the US. This paper offers a 12 methodology that could be used to assess cost-effectiveness of DMOADs in other countries, 13 using country specific data on OA natural history, progression and treatment costs. 14
15
The results of our analyses showed that in the absence of DMOADs the lifetime risk of TKR among 16 those with symptomatic knee OA approached 50%. These results suggest higher TKR rates than 17 estimated in data derived from large cohort studies such as the Osteoarthritis Initiative (OAI) 52 . There 18 are several reasons for the difference between our model-based estimates and OAI data: 1) persons 19 intending to undergo TKR within 18 months were excluded from OAI, and 2) OAI-based estimates, 20 which indicate a 1%/year conversion to TKR, include data from both incident and prevalent cohorts, 21 with a substantial number of persons at K-L grade 1. In contrast, our model-based estimates used 22 incidence of TKR data derived from the Multicenter Osteoarthritis Study (MOST) study, which assumes 23 that only subjects with K-L grade 3 or greater were eligible for TKR. Among subjects in the OAI with K-L 24 grade 3 or 4 OA, the conversion to TKR was estimated at about 10%/year 52, 53 . Furthermore, this rate of 1 conversion to TKR among those at K-L grade 3 or 4 was consistent with nationwide estimates of the 2 number of TKRs performed in the US 54 . 3 4 Although we only modeled the use of one DMOAD as part of the OA treatment sequence, it is likely that 5 multiple DMOADs will ultimately become available to patients. It is also possible that DMOADs are 6 more likely to offer pain relief for subjects who are K-L grade 2, before the degeneration of the knee 7 joint reaches an advanced state, than for subjects who are K-L grade 3. However, we did not model 8 varying levels of pain relief based on current K-L grade. In this case, it would be critical to offer 9
DMOADs early in the treatment sequence, thus catching patients before they progress to more severe 10
OA. 11 12
To the best of our knowledge, the results of the analyses documented here comprise the first pre-13 evaluation of the effectiveness, costs, and cost-effectiveness of DMOAD therapy for knee OA. We have 14 examined the sensitivity of DMOAD value to variations in a wide spectrum of characteristics, most 15 notably efficacy, toxicity, and costs. Our findings may provide critical insights for clinical trial planning 16 and ensure that drug manufacturers focus the development of new regimens on parameters that will 17 affect quality of life, in particular, pain relief. These analyses also offer a new approach in which 18 simulation modeling can be efficiently used to evaluate new treatment strategies under development 19 before the implementation of costly clinical trials. 
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